ONCAlert | Upfront Therapy for mRCC

Melanoma VIEW MORE >>

In an interview with Targeted Oncology, Jeffrey S.Weber, MD, PhD, discussed the 3-year efficacy and biomarker results from the phase III CheckMate 238 trial, which he presented at the 2019 ESMO Congress.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.